Related Experiment Videos
Adjuvant medical therapy in peripheral bypass surgery
H R Watson1, G Belcher, M Horrocks
1School of Postgraduate Medicine, University of Bath, London, UK.
The British Journal of Surgery
|August 25, 1999
Summary
Adjuvant medical therapy for infrainguinal bypass grafts shows limited evidence due to trial design flaws. Only aspirin and ticlopidine demonstrate efficacy in specific graft types.
Area of Science:
- Vascular Surgery
- Pharmacology
- Clinical Trial Methodology
Background:
- Review of adjuvant medical therapy in infrainguinal bypass procedures.
- Evaluation of evidence strength for various therapeutic agents.
- Focus on optimizing graft patency and patient outcomes.
Purpose of the Study:
- To critically assess the quality of evidence supporting medical therapies for infrainguinal bypass grafts.
- To identify agents with proven efficacy based on robust clinical trial data.
- To highlight deficiencies in existing research methodologies.
Main Methods:
- Systematic literature search for published clinical trials.
- Review of study designs, including randomization and blinding.
- Assessment of reported clinical outcomes and statistical significance.
Main Results:
- Thirty-three trials were identified; less than half were randomized and double-blind.
- Most studies were single-center with heterogeneous patient populations and procedures.
- Aspirin (prosthetic grafts) and ticlopidine (vein grafts) showed efficacy in high-quality trials.
Conclusions:
- Significant design deficiencies in most trials limit the reliability of their findings.
- Further well-designed studies are necessary to establish the effectiveness of medical therapies.
- Evidence supports aspirin for prosthetic and ticlopidine for vein infrainguinal bypass grafts.